Sapacitabine

Cyclacel AML drug fails phase 3, wiping 30% off stock

Cyclacel has learnt sapacitabine is no better at improving overall survival in elderly patients with AML than decitabine, triggering a 30% stock drop.

Nick Paul Taylor Feb 23, 2017 8:37am